Revolution Medicines, Inc. (RVMD) Financial Statements
Revolution Medicines, Inc. (RVMD) reported trailing twelve-month revenue of $0 (up 550.3% year on year) and net income of -$1.8B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$1.2B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RVMDRevolution Medicines, Inc.Follow RVMD — free
—
Price chart with a free account
- Market cap
- 40.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.04 | 0.03 | 0.04 | 0.01 | 0.00 | 0.00 | — | |
| Research & development | 0.13 | 0.19 | 0.25 | 0.42 | 0.59 | 0.99 | 1.30 | |
| Operating income | -0.11 | -0.19 | -0.26 | -0.49 | -0.69 | -1.18 | -1.63 | |
| Pre-tax income | -0.11 | -0.19 | -0.25 | -0.44 | -0.60 | -1.13 | -1.77 | |
| Income tax | -0.00 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 | — | |
| Net income | -0.11 | -0.19 | -0.25 | -0.44 | -0.60 | -1.13 | -1.77 | |
| Diluted EPS ($) | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 | -8.85 | |
| Diluted shares (bn) | — | — | 0.081 | 0.113 | 0.168 | 0.190 | — |
USD billions · SEC XBRL
Revolution Medicines, Inc. — questions
- What is Revolution Medicines, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 550.3% year on year, from its 10-Q and 10-K filings.
- What is Revolution Medicines, Inc.'s net income?
- -$1.8B over the twelve months to 2026-06-30.
- What is Revolution Medicines, Inc.'s free cash flow?
- -$1.2B over the twelve months to 2026-06-30.
- What are Revolution Medicines, Inc.'s diluted earnings per share?
- $-8.85 over the twelve months to 2026-06-30.
Every figure on this page comes from Revolution Medicines, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.